# A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

> **NCT06507306** · PHASE1 · RECRUITING · sponsor: **Kumquat Biosciences Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** KQB198
- **DRUG:** Osimertinib
- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT06507306
- **Lead sponsor:** Kumquat Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507306, "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06507306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*